Carregant...
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
Bladder cancer is the sixth most common cancer in the US and most tumors have urothelial (transitional cell) histology. Platinum-based chemotherapy has long been the standard of care in advanced disease, but long-term outcomes have largely remained poor. Since the peak incidence of bladder cancer is...
Guardat en:
| Publicat a: | Ther Clin Risk Manag |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5993034/ https://ncbi.nlm.nih.gov/pubmed/29892196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S158753 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|